Royalty Report: Drugs, Vaccine, Therapeutic – Collection: 1544

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Vaccine
  • Therapeutic
  • Biotechnology
  • Viral Infection
  • HIV / AIDs

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 1544

License Grant
Licensor hereby grants a worldwide non-exclusive, royalty bearing license in the Field, under Licensor's Patent Rights and Licensor's Know-How, without the right to grant sublicenses for the purpose of performing preclinical research under this Agreement and with the right to grant such sublicenses to develop, make, have made, use and sell Products and Target Products in the Field, in each case in accordance with the terms and conditions of this Agreement.  The Company has licensed its technology relating to genes and gene sequencing.
License Property
Assembled  Genome shall mean the final results of the genome assembly of a Streptococcus pneumoniae strain. Immunotherapeutics shall mean products incorporating antibodies and/or fragments thereof and/or derivatives thereof derived from Technology, which have a protective or therapeutic effect against infectious agents.
Field of Use
Field shall mean the prevention, diagnosis or treatment of infectious diseases in humans excluding Vaccines and Immunotherapeutics.

IPSCIO Record ID: 375061

License Grant
Licensor, a research hospital, grants to Licensee an exclusive, worldwide license to certain specified patent rights and biological materials relating to the use of live attenuated streptococcus pneumoniae and practice processes that are covered by the licensed patent rights and biological materials for the purpose of developing and commercializing a vaccine product candidate for streptococcus pneumoniae.
License Property
Patent rights and biological materials include but not limited to BWV-201.

BWV-201 is a live attenuated serotype-independent intranasal vaccine candidate for S. pneumoniae induced AOM (Acute Otitis Media). BWV-201 has the ability to transiently colonize the nasopharyngeal cavity and significantly decrease the incidence of AOM and sinusitis in animal models. The vaccine candidate is derived from the noninvasive serotype 19F strain BHN97.

9,265,819 – Live, attenuated Streptococcus pneumoniae strain and vaccine for protection against pneumococcal disease

Field of Use
Field of use is for the treatment of streptococcus pneumoniae.

Streptococcus pneumoniae is the main cause of community acquired pneumonia and meningitis in children and the elderly, and of sepsis in those infected with HIV.

IPSCIO Record ID: 328343

License Grant
Licensor grants to Licensee an exclusive license under Licensor know-how and Licensor Patent Rights to develop, make, have made, use and sell Licensed Products in the territory with the right to grant sublicenses to affiliates of Licensee and those persons or entities through whom Licensee,  in the normal course of its business collaborates in the manufacture and sale of its products; provided, however, that nothing in this Agreement shall prohibit Licensor from utilizing the Licensor know-how and/or Licensor Patent Rights, exclusive of Licensee Know-how, to develop, make, have made, use and sell, either by itself or with one or more third  parties, products for the treatment of human infectious diseases.
License Property
Technology pertaining to the intramuscular delivery of vaccines for the prevention of human infectious disease that consist of DNA and/or RNA gene sequences derived from the genome of the infectious agent which would prevent clinical disease from an infection.

AIDS Vaccine means a vaccine which would prevent an infection by Human Immunodeficiency Virus (HIV-1) and/or clinical diseases caused by infection with HIV-1 in humans.

Influenza Vaccine means a vaccine which would prevent an infection and/or significant clinical diseases caused by any influenza virus in humans.

Licensed Product means a bulk or finished AIDS Vaccine or Influenza Vaccine, or other vaccine for the prevention of human infectious disease if licensed hereunder, which utilizes the Technology or technology which is developed by Licensor during and as a result of the Research Collaboration Program; provided, however, that if any such vaccine is also capable of being used for treatment of the same human infectious disease, then such therapeutic use of such vaccine shall also be considered a Licensed Product for purposes of the license being granted by Licensor to Licensee under this Agreement.

Field of Use
Field of Use is for the prevention of human infectious disease.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.